Florida bill advances

Article

 

Tallahassee, FL-At press time, Florida optometrists were awaiting a vote in the Florida Senate appropriations committee on SB278, a bill which would grant additional prescribing authority to optometrists. Previously, the Florida Senate voted 10-0 to approve SB278.

“Originally it was to be voted on by the full Senate as a special calendar item, but it was decided to go the regular, full-three-reading route,” says Kimberly Reed, OD, FAAO, associate professor at Nova Southeastern University College of Optometry. Dr. Reed provided testimony during hearings for SB278.

The bill would grant optometrists the ability to prescribe oral medication, in the language of SB278: “requiring a certified optometrist to complete a course and examination on general and ocular pharmaceutical agents before administering or prescribing oral ocular pharmaceutical agents.”

A similar bill, HB239, recently passed the Florida House 116-0. “I am very pleased that we seem to have come to an agreement on this bill. It was the direct result of many discussions by interested individuals working on behalf of the patients in the state of Florida,” says Dr. Reed.ODT

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
© 2025 MJH Life Sciences

All rights reserved.